B1 & B2 Raw Materials for Premix Manufacturers

Match the ingredient form to the premix specification

Premix manufacturers need a defined raw material, not simply a vitamin category. The available B1 form is thiamine mononitrate and the B2 form is riboflavin. Confirm that those identities match the approved formulation and purchasing specification before evaluating commercial availability. This page does not offer a finished premix, a formulation service or a guarantee that either material fits every premix process. The appropriate review depends on the intended end use and the buyer's technical controls. State the application in the inquiry so QA documentation and commercial discussions address the same requirement rather than a generic bulk-vitamin purchase.

Review attributes beyond assay

An assay is important, but a premix decision can also depend on the buyer's identity, moisture, impurity, handling and other specifications. The public B1 profile provides several analytical summary values; the B2 position is described through lot-specific COAs and independent Sigma assays. Request the full technical package and identify any additional attributes your manufacturing process requires. Do not assume particle-size, flow, blending, stability or finished-premix performance from the published assay percentages. Those are questions to resolve through the relevant documentation and your own qualification process. A supplier summary should support an initial review without replacing process-specific evaluation.

Plan raw-material approval around lot allocation

The B1 position is 1,500 kg from one documented batch. B2 is available as 1,000 kg in lot 2025052801 and 500 kg in lot 2025052901. Their independent assays are 98.88% and 99.65%, respectively, so a purchasing record should not treat them as one undifferentiated source. If your premix production plan requires a single approved lot, make that condition explicit in the inquiry. If both B2 lots are under consideration, review both certificates and preserve separate traceability records. Commercial allocation should follow the material your technical team has assessed, particularly when a procurement quantity spans more than one lot.

Connect inventory timing with production planning

The material is already warehoused in South Carolina in palletized 20 kg fiber drums, allowing domestic freight to be discussed without starting a new overseas supply cycle for this stock. Provide the required kilograms, receiving destination and required-by date to establish whether the current position fits your schedule. Keep QA approval, sample evaluation and supplier onboarding in that plan; warehouse readiness alone does not authorize production use. Review manufacture and expiry dates against anticipated consumption. Ask for freight and dispatch terms in a commercial quote rather than assuming that immediate availability means a fixed arrival date or reserved inventory.

Keep application qualification explicit

Different premix end uses may create different regulatory and grade requirements. No pharmaceutical, food, feed or other application status should be inferred merely from the product names or the website's quality positioning. Provide your required standard and intended use, then let your QA and regulatory teams evaluate the source documentation. Qualified buyers can request the COA package, independent testing records and supporting material as available, with an NDA where needed. Mention whether a sample is part of your approval process. Once the technical conditions are clear, request a commercial quote that specifies the product, lot allocation, quantity, destination and timing for the proposed purchase.

Separate raw-material evidence from blending performance

A raw-material certificate reports attributes of the tested ingredient; it is not a validation of your finished premix. Your formulation and manufacturing teams should determine which additional evaluations are needed for their process and intended use. If a particular physical property or handling requirement matters, include it in the request and ask what source evidence is available. Do not assume a blending or stability outcome from the independent assay alone. This distinction keeps the procurement discussion useful: the supplier provides documentation for the material offered, while the buyer determines how to evaluate that material within the approved production process and finished-product requirements.

The inquiry should distinguish an initial trial requirement from a routine commercial purchase. State whether your team needs documentation first, a sample for evaluation or a quote for a defined production quantity. Identify the product form and proposed lot so the trial and commercial discussions do not drift toward different inventory records. If the eventual purchase spans both B2 lots, confirm whether your qualification procedure must evaluate both. Keep any application or grade conditions explicit in the approval record. This page targets professional premix procurement without claiming that the available raw materials are pre-approved for every human or animal application, every formulation or every market.